Sponsor & Developer Portfolio
Janssen (Johnson & Johnson)
Clinical development pipeline, platform architecture, and registered trial tracking for Janssen (Johnson & Johnson) vaccine candidates.
4
Candidates
3
Target Diseases
4
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 4
Platform Technologies
Viral vector: 2 Biological (unspecified platform): 1 Live attenuated: 1
Target Pathogens & Indications
Carcinoma, Non-Small-Cell Lung Ebola RSV
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-ad26-zebov-janssen-vaccines-prevention-b-v
Ad26.ZEBOV
Target: Ebola
Platform: Viral vector
Key Milestone: Primary completion (most advanced trial): 2021-12-13 (registry estimate)
Discontinued / Inactive
ctgov-ad26-protein-pref-rsv-vaccine-janssen-pharmaceutical-k-k
Ad26/protein preF RSV Vaccine
Target: RSV
Platform: Viral vector
Key Milestone: Primary completion (most advanced trial): 2023-03-20 (registry estimate)
Discontinued / Inactive
ctgov-jnj-64041757-cohort-1a-and-1b-janssen-research-development-llc
JNJ-64041757 (Cohort 1A and 1B)
Target: Carcinoma, Non-Small-Cell Lung
Platform: Live attenuated
Key Milestone: Primary completion (most advanced trial): 2018-08-14 (registry estimate)
Discontinued / Inactive
ctgov-rsv-pref-based-vaccine-janssen-vaccines-prevention-b-v
RSV preF-based Vaccine
Target: RSV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2023-01-16 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.